These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

710 related articles for article (PubMed ID: 18052601)

  • 1. N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance.
    Yap SH; Sheen CW; Fahey J; Zanin M; Tyssen D; Lima VD; Wynhoven B; Kuiper M; Sluis-Cremer N; Harrigan PR; Tachedjian G
    PLoS Med; 2007 Dec; 4(12):e335. PubMed ID: 18052601
    [TBL] [Abstract][Full Text] [Related]  

  • 2. N348I in reverse transcriptase provides a genetic pathway for HIV-1 to select thymidine analogue mutations and mutations antagonistic to thymidine analogue mutations.
    Radzio J; Yap SH; Tachedjian G; Sluis-Cremer N
    AIDS; 2010 Mar; 24(5):659-67. PubMed ID: 20160634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frequent emergence of N348I in HIV-1 subtype C reverse transcriptase with failure of initial therapy reduces susceptibility to reverse-transcriptase inhibitors.
    Brehm JH; Koontz DL; Wallis CL; Shutt KA; Sanne I; Wood R; McIntyre JA; Stevens WS; Sluis-Cremer N; Mellors JW;
    Clin Infect Dis; 2012 Sep; 55(5):737-45. PubMed ID: 22618567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance.
    Gupta S; Fransen S; Paxinos EE; Stawiski E; Huang W; Petropoulos CJ
    Antimicrob Agents Chemother; 2010 May; 54(5):1973-80. PubMed ID: 20194692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The connection domain mutation N348I in HIV-1 reverse transcriptase enhances resistance to etravirine and rilpivirine but restricts the emergence of the E138K resistance mutation by diminishing viral replication capacity.
    Xu HT; Colby-Germinario SP; Oliveira M; Han Y; Quan Y; Zanichelli V; Wainberg MA
    J Virol; 2014 Feb; 88(3):1536-47. PubMed ID: 24227862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Should we include connection domain mutations of HIV-1 reverse transcriptase in HIV resistance testing.
    Götte M
    PLoS Med; 2007 Dec; 4(12):e346. PubMed ID: 18052605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phenotypic characterization of drug resistance-associated mutations in HIV-1 RT connection and RNase H domains and their correlation with thymidine analogue mutations.
    Lengruber RB; Delviks-Frankenberry KA; Nikolenko GN; Baumann J; Santos AF; Pathak VK; Soares MA
    J Antimicrob Chemother; 2011 Apr; 66(4):702-8. PubMed ID: 21393163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidemiological and biological evidence for a compensatory effect of connection domain mutation N348I on M184V in HIV-1 reverse transcriptase.
    von Wyl V; Ehteshami M; Symons J; Bürgisser P; Nijhuis M; Demeter LM; Yerly S; Böni J; Klimkait T; Schuurman R; Ledergerber B; Götte M; Günthard HF;
    J Infect Dis; 2010 Apr; 201(7):1054-62. PubMed ID: 20170373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A376S in the connection subdomain of HIV-1 reverse transcriptase confers increased risk of virological failure to nevirapine therapy.
    Paredes R; Puertas MC; Bannister W; Kisic M; Cozzi-Lepri A; Pou C; Bellido R; Betancor G; Bogner J; Gargalianos P; Bánhegyi D; Clotet B; Lundgren J; Menéndez-Arias L; Martinez-Picado J;
    J Infect Dis; 2011 Sep; 204(5):741-52. PubMed ID: 21844300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amino acid mutation N348I in the connection subdomain of human immunodeficiency virus type 1 reverse transcriptase confers multiclass resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors.
    Hachiya A; Kodama EN; Sarafianos SG; Schuckmann MM; Sakagami Y; Matsuoka M; Takiguchi M; Gatanaga H; Oka S
    J Virol; 2008 Apr; 82(7):3261-70. PubMed ID: 18216099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selection of mutations in the connection and RNase H domains of human immunodeficiency virus type 1 reverse transcriptase that increase resistance to 3'-azido-3'-dideoxythymidine.
    Brehm JH; Koontz D; Meteer JD; Pathak V; Sluis-Cremer N; Mellors JW
    J Virol; 2007 Aug; 81(15):7852-9. PubMed ID: 17507476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subunit-specific mutational analysis of residue N348 in HIV-1 reverse transcriptase.
    Radzio J; Sluis-Cremer N
    Retrovirology; 2011 Aug; 8():69. PubMed ID: 21859446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Positive and negative drug selection pressures on the N348I connection domain mutation: new insights from in vivo data.
    Price H; Asboe D; Pozniak A; Gazzard B; Fearnhill E; Pillay D; Dunn D; ;
    Antivir Ther; 2010; 15(2):203-11. PubMed ID: 20386075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms by which the G333D mutation in human immunodeficiency virus type 1 Reverse transcriptase facilitates dual resistance to zidovudine and lamivudine.
    Zelina S; Sheen CW; Radzio J; Mellors JW; Sluis-Cremer N
    Antimicrob Agents Chemother; 2008 Jan; 52(1):157-63. PubMed ID: 17967907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen.
    Delaugerre C; Rohban R; Simon A; Mouroux M; Tricot C; Agher R; Huraux JM; Katlama C; Calvez V
    J Med Virol; 2001 Nov; 65(3):445-8. PubMed ID: 11596076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. N348I in HIV-1 reverse transcriptase counteracts the synergy between zidovudine and nevirapine.
    Yap SH; Herman BD; Radzio J; Sluis-Cremer N; Tachedjian G
    J Acquir Immune Defic Syndr; 2012 Oct; 61(2):153-7. PubMed ID: 22743599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical relevance of substitutions in the connection subdomain and RNase H domain of HIV-1 reverse transcriptase from a cohort of antiretroviral treatment-naïve patients.
    Hachiya A; Shimane K; Sarafianos SG; Kodama EN; Sakagami Y; Negishi F; Koizumi H; Gatanaga H; Matsuoka M; Takiguchi M; Oka S
    Antiviral Res; 2009 Jun; 82(3):115-21. PubMed ID: 19428602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. N348I in HIV-1 reverse transcriptase can counteract the nevirapine-mediated bias toward RNase H cleavage during plus-strand initiation.
    Biondi MJ; Beilhartz GL; McCormick S; Götte M
    J Biol Chem; 2010 Aug; 285(35):26966-26975. PubMed ID: 20530477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Connection domain mutations N348I and A360V in HIV-1 reverse transcriptase enhance resistance to 3'-azido-3'-deoxythymidine through both RNase H-dependent and -independent mechanisms.
    Ehteshami M; Beilhartz GL; Scarth BJ; Tchesnokov EP; McCormick S; Wynhoven B; Harrigan PR; Götte M
    J Biol Chem; 2008 Aug; 283(32):22222-32. PubMed ID: 18547911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The N348I mutation at the connection subdomain of HIV-1 reverse transcriptase decreases binding to nevirapine.
    Schuckmann MM; Marchand B; Hachiya A; Kodama EN; Kirby KA; Singh K; Sarafianos SG
    J Biol Chem; 2010 Dec; 285(49):38700-9. PubMed ID: 20876531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.